BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017;66:342-351. [PMID: 26669617 DOI: 10.1136/gutjnl-2015-310814] [Cited by in Crossref: 162] [Cited by in F6Publishing: 159] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Pelizzaro F, Vitale A, Sartori A, Vieno A, Penzo B, Russo FP, Frigo AC, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Marra F, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Coccoli P, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F, On Behalf Of Ita Li Ca Study Group. Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers (Basel) 2021;13:897. [PMID: 33672751 DOI: 10.3390/cancers13040897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Guo H, Tsung K. Tumor reductive therapies and antitumor immunity. Oncotarget 2017;8:55736-49. [PMID: 28903456 DOI: 10.18632/oncotarget.18469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kaplon H, Dieu-nosjean M. Quel avenir pour les lymphocytes B infiltrant les tumeurs solides: Marqueur pronostique et/ou cible thérapeutique ? Med Sci (Paris) 2018;34:72-8. [DOI: 10.1051/medsci/20183401016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
5 Jiang S, Zhang J, Bian J, Zhang L, Xu Y, Zhao H, Sang X, Lu X. Novel nomograms based on immune and stromal scores for predicting the disease-free and overall survival of patients with hepatocellular carcinoma undergoing radical surgery. J Surg Oncol 2020;122:1569-79. [PMID: 32885449 DOI: 10.1002/jso.26197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cai S, Hu X, Chen R, Zhang Y. Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma. Front Genet 2021;12:657051. [PMID: 34178028 DOI: 10.3389/fgene.2021.657051] [Reference Citation Analysis]
7 Kim SH, Lee EC, Na BG, Park SJ. Impact of ABO-incompatibility on hepatocellular carcinoma recurrence after living donor liver transplantation. Eur J Surg Oncol 2019;45:180-6. [PMID: 30243467 DOI: 10.1016/j.ejso.2018.07.066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Hetta HF, Mekky MA, Zahran AM, Abdel-Malek MO, Ramadan HK, Shafik EA, Abbas WA, Abbas El-Masry M, Mohamed NA, Kamel AA, Marraiki N, Beshbishy AM, Batiha GE, Osman HA, Koneru G, El-Mokhtar MA. Regulatory B Cells and Their Cytokine Profile in HCV-Related Hepatocellular Carcinoma: Association with Regulatory T Cells and Disease Progression. Vaccines (Basel) 2020;8:E380. [PMID: 32664587 DOI: 10.3390/vaccines8030380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
10 Yao W, He JC, Yang Y, Wang JM, Qian YW, Yang T, Ji L. The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis. Sci Rep 2017;7:7525. [PMID: 28790445 DOI: 10.1038/s41598-017-08128-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 14.0] [Reference Citation Analysis]
11 Duffy AG, Greten TF. Treating Hepatobiliary Cancer: The Immunologic Approach. Dig Dis 2017;35:390-6. [PMID: 28468006 DOI: 10.1159/000456593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Liu Z, Zhang Y, Shi C, Zhou X, Xu K, Jiao D, Sun Z, Han X. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. J Transl Med 2021;19:5. [PMID: 33407585 DOI: 10.1186/s12967-020-02697-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
13 Soldevilla MM, Villanueva H, Meraviglia-Crivelli D, Menon AP, Ruiz M, Cebollero J, Villalba M, Moreno B, Lozano T, Llopiz D, Pejenaute Á, Sarobe P, Pastor F. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. Mol Ther 2019;27:1878-91. [PMID: 31405808 DOI: 10.1016/j.ymthe.2019.07.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
14 Ning G, Huang YL, Zhen LM, Xu WX, Li XJ, Wu LN, Liu Y, Xie C, Peng L. Prognostic Value of Complement Component 2 and Its Correlation with Immune Infiltrates in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:3765937. [PMID: 32626741 DOI: 10.1155/2020/3765937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Li J, Zhou J, Kai S, Wang C, Wang D, Jiang J. Network-Based Coexpression Analysis Identifies Functional and Prognostic Long Noncoding RNAs in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:1371632. [PMID: 33083449 DOI: 10.1155/2020/1371632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lin CH, Elkholy KH, Wani NA, Li D, Hu P, Barajas JM, Yu L, Zhang X, Jacob ST, Khan WN, Bai XF, Noonan AM, Ghoshal K. Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma. Mol Cancer Ther 2020;19:384-96. [PMID: 31582534 DOI: 10.1158/1535-7163.MCT-19-0135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
17 Abolarinwa BA, Ibrahim RB, Huang YH. Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. Int J Mol Sci 2019;20:E4624. [PMID: 31540435 DOI: 10.3390/ijms20184624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ren S, Wang W, Zhang C, Sun Y, Sun M, Wang Y, Zhang X, Lu B, Yao L. The low expression of NUP62CL indicates good prognosis and high level of immune infiltration in lung adenocarcinoma. Cancer Med 2021;10:3403-12. [PMID: 33934535 DOI: 10.1002/cam4.3877] [Reference Citation Analysis]
19 Sugio T, Miyawaki K, Kato K, Sasaki K, Yamada K, Iqbal J, Miyamoto T, Ohshima K, Maeda T, Miyoshi H, Akashi K. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv 2018;2:2242-52. [PMID: 30194138 DOI: 10.1182/bloodadvances.2018018754] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
20 Li J, Yan K, Yang Y, Li H, Wang Z, Xu X. [Interleukin-17 promotes mouse hepatoma cell proliferation by antagonizing interferon-γ]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:1-5. [PMID: 30692059 DOI: 10.12122/j.issn.1673-4254.2019.01.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 [DOI: 10.1101/549659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Tian M, Zhou Y, Qu W, Liu W, Jin L, Jiang X, Wang H, Tao C, Zhou P, Fang Y, Ding Z, Peng Y, Zhou J, Fan J, Shi Y. Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. Cancer Immunol Immunother 2019;68:1369-78. [DOI: 10.1007/s00262-019-02371-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018;37:327. [PMID: 30594216 DOI: 10.1186/s13046-018-1002-1] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 31.7] [Reference Citation Analysis]
24 Roderburg C, Wree A, Demir M, Schmelzle M, Tacke F. The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepat Oncol 2020;7:HEP17. [PMID: 32273975 DOI: 10.2217/hep-2019-0007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
25 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1922. [PMID: 33923463 DOI: 10.3390/cancers13081922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Goldaracena N, Barbas AS. Living donor liver transplantation. Curr Opin Organ Transplant. 2019;24:131-137. [PMID: 30694993 DOI: 10.1097/mot.0000000000000610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
27 Khlaiphuengsin A, Chuaypen N, Sodsai P, Buranapraditkun S, Boonpiyathad T, Hirankarn N, Tangkijvanich P. Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2020;26:2645-56. [PMID: 32523317 DOI: 10.3748/wjg.v26.i20.2645] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Ding H, Hu H, Tian F, Liang H. A dual immune signature of CD8+ T cells and MMP9 improves the survival of patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20204219. [PMID: 33656546 DOI: 10.1042/BSR20204219] [Reference Citation Analysis]
29 Lim CJ, Nguyen PHD, Wasser M, Kumar P, Lee YH, Nasir NJM, Chua C, Lai L, Hazirah SN, Loh JJH, Khor LY, Yeong J, Lim TKH, Low AWX, Albani S, Chong TW, Chew V. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer. Front Immunol 2020;11:615091. [PMID: 33584702 DOI: 10.3389/fimmu.2020.615091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Huang YH, Zhang CZ, Huang QS, Yeong J, Wang F, Yang X, He YF, Zhang XL, Zhang H, Chen SL, Zheng YL, Deng R, Lin CS, Yang MM, Li Y, Jiang C, Kin-Wah Lee T, Ma S, Zeng MS, Yun JP. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Hepatol 2021;74:838-49. [PMID: 33212090 DOI: 10.1016/j.jhep.2020.10.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Jiang H, Ning G, Wang Y, Lv W. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. Dis Markers 2021;2021:5576683. [PMID: 34221187 DOI: 10.1155/2021/5576683] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Barrow F, Khan S, Wang H, Revelo XS. The Emerging Role of B Cells in the Pathogenesis of NAFLD. Hepatology 2021. [PMID: 33961302 DOI: 10.1002/hep.31889] [Reference Citation Analysis]
33 Gao F, Xie K, Xiang Q, Qin Y, Chen P, Wan H, Deng Y, Huang J, Wu H. The density of tumor-infiltrating lymphocytes and prognosis in resectable hepatocellular carcinoma: a two-phase study. Aging (Albany NY) 2021;13:9665-78. [PMID: 33744864 DOI: 10.18632/aging.202710] [Reference Citation Analysis]
34 Lee B, Hutchinson R, Wong HL, Tie J, Putoczki T, Tran B, Gibbs P, Christie M. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Semin Cancer Biol. 2018;52:241-252. [PMID: 29258858 DOI: 10.1016/j.semcancer.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
35 Meng Q, Valentini D, Rao M, Maeurer M. KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer. Front Oncol 2018;8:384. [PMID: 30283732 DOI: 10.3389/fonc.2018.00384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
36 Hage C, Hoves S, Ashoff M, Schandl V, Hört S, Rieder N, Heichinger C, Berrera M, Ries CH, Kiessling F, Pöschinger T. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. PLoS One 2019;14:e0219517. [PMID: 31291357 DOI: 10.1371/journal.pone.0219517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
37 Lu G, Chen L, Wu S, Feng Y, Lin T. Comprehensive Analysis of Tumor-Infiltrating Immune Cells and Relevant Therapeutic Strategy in Esophageal Cancer. Dis Markers 2020;2020:8974793. [PMID: 32454908 DOI: 10.1155/2020/8974793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Soldevilla MM, Villanueva H, Martinez-Velez N, Meraviglia-Crivelli D, Alonso MM, Cebollero J, Menon AP, Puigdelloses M, Pastor F. Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors. Oncoimmunology 2018;7:e1450711. [PMID: 30221041 DOI: 10.1080/2162402X.2018.1450711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Borhani AA, Catania R, Velichko YS, Hectors S, Taouli B, Lewis S. Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response. Abdom Radiol (NY) 2021;46:3674-85. [PMID: 33891149 DOI: 10.1007/s00261-021-03085-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
41 Lin T, Lin Z, Mai P, Zhang E, Peng L. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma. Aging (Albany NY) 2021;13:11786-807. [PMID: 33878734 DOI: 10.18632/aging.202876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68:1025-1041. [PMID: 29603348 DOI: 10.1002/hep.29904] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 34.3] [Reference Citation Analysis]
43 Zhang Q, Lou Y, Bai XL, Liang TB. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. World J Gastroenterol 2018;24:3500-12. [PMID: 30131656 DOI: 10.3748/wjg.v24.i31.3500] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
44 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Reference Citation Analysis]
45 Rimini M, Yoo C, Lonardi S, Masi G, Piscaglia F, Kim HD, Rizzato MD, Salani F, Ielasi L, Forgione A, Bang Y, Soldà C, Catanese S, Sansone V, Ryu MH, Ryoo BY, Burgio V, Cucchetti A, Cascinu S, Casadei-Gardini A. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. Hepatol Res 2021;51:796-802. [PMID: 34005839 DOI: 10.1111/hepr.13669] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Mi K, Chen F, Qian Z, Chen J, Lv D, Zhang C, Xu Y, Wang H, Zhang Y, Jiang Y, Shang D. Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes. J Cell Mol Med 2020;24:14608-18. [PMID: 33184998 DOI: 10.1111/jcmm.16092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Zdziarski P, Gamian A. Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency - Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens. Front Pharmacol 2018;9:1559. [PMID: 30713498 DOI: 10.3389/fphar.2018.01559] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
48 He Y, Xu R, Peng L, Hu X. Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis. PLoS One 2021;16:e0254829. [PMID: 34324544 DOI: 10.1371/journal.pone.0254829] [Reference Citation Analysis]
49 Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF, Lim JCT, Yeong J, Lim TKH. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun (Lond) 2020;40:135-53. [PMID: 32301585 DOI: 10.1002/cac2.12023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 53.0] [Reference Citation Analysis]
50 Zhu J, Wang L, Zhou Y, Hao J, Wang S, Liu L, Li J. Comprehensive analysis of the relationship between competitive endogenous RNA (ceRNA) networks and tumor infiltrating-cells in hepatocellular carcinoma. J Gastrointest Oncol 2020;11:1381-98. [PMID: 33457008 DOI: 10.21037/jgo-20-555] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Fan J, Li J, Han J, Zhang Y, Gu A, Song F, Duan J, Yin D, Wang L, Yi Y. Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma. Mol Immunol 2021;136:82-97. [PMID: 34098344 DOI: 10.1016/j.molimm.2021.05.011] [Reference Citation Analysis]
52 Yang YM, Kim SY, Seki E. Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets. Semin Liver Dis. 2019;39:26-42. [PMID: 30809789 DOI: 10.1055/s-0038-1676806] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 28.0] [Reference Citation Analysis]
53 Schoenberg MB, Li X, Li X, Han Y, Hao J, Miksch RC, Koch D, Börner N, Beger NT, Bucher JN, Schiergens TS, Guba MO, Werner J, Bazhin AV. The predictive value of tumor infiltrating leukocytes in Hepatocellular Carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2021:S0748-7983(21)00473-X. [PMID: 33966947 DOI: 10.1016/j.ejso.2021.04.042] [Reference Citation Analysis]
54 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
55 Wu F, Wei H, Liu G, Zhang Y. Bioinformatics Profiling of Five Immune-Related lncRNAs for a Prognostic Model of Hepatocellular Carcinoma. Front Oncol 2021;11:667904. [PMID: 34123835 DOI: 10.3389/fonc.2021.667904] [Reference Citation Analysis]
56 Maruyama H, Yamaguchi T, Nagamatsu H, Shiina S. AI-Based Radiological Imaging for HCC: Current Status and Future of Ultrasound. Diagnostics (Basel) 2021;11:292. [PMID: 33673229 DOI: 10.3390/diagnostics11020292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
57 Koo SY, Park EJ, Lee CW. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp Mol Med 2020;52:1209-19. [PMID: 32770081 DOI: 10.1038/s12276-020-0480-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
58 Kurebayashi Y, Kubota N, Sakamoto M. Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatol Res 2021;51:5-18. [DOI: 10.1111/hepr.13539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
59 Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, Tay TKY, Selvarajan S, Md Nasir ND, Loh JH, Ong CK, Huang D, Tan J, Li Z, Ng CC, Tan TT, Masuzawa M, Sung KW, Farid M, Quek RHH, Tan NC, Teo MCC, Rozen SG, Tan P, Futreal A, Teh BT, Soo KC. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. J Clin Invest 2020;130:5833-46. [PMID: 33016928 DOI: 10.1172/JCI139080] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 15.0] [Reference Citation Analysis]
60 Lu K, He C, Guo N, Chan C, Ni K, Lan G, Tang H, Pelizzari C, Fu Y, Spiotto MT, Weichselbaum RR, Lin W. Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng 2018;2:600-10. [DOI: 10.1038/s41551-018-0203-4] [Cited by in Crossref: 235] [Cited by in F6Publishing: 180] [Article Influence: 78.3] [Reference Citation Analysis]
61 Shang J, Zha H, Sun Y. Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer. Front Immunol 2020;11:582657. [PMID: 33193391 DOI: 10.3389/fimmu.2020.582657] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
62 Yu H, Zhu X, Lin H, Pan H, Zhao F, Zhu M, Sun L, Chai W, Yao M, Yan M. A new risk model comprising genes highly correlated with CD133 identifies different tumor-immune microenvironment subtypes impacting prognosis in hepatocellular carcinoma. Aging (Albany NY) 2020;12:12234-50. [PMID: 32564007 DOI: 10.18632/aging.103409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
63 Pivetta E, Spessotto P. Multispectral imaging technology: Visualize, analyze, phenotyping, and quantify immune cells in situ. Int J Biol Markers 2020;35:26-30. [PMID: 32079464 DOI: 10.1177/1724600819896810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
64 Mungenast F, Fernando A, Nica R, Boghiu B, Lungu B, Batra J, Ecker RC. Next-Generation Digital Histopathology of the Tumor Microenvironment. Genes (Basel) 2021;12:538. [PMID: 33917241 DOI: 10.3390/genes12040538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Liu WR, Tian MX, Tang Z, Fang Y, Zhou YF, Song SS, Jiang XF, Wang H, Tao CY, Zhou PY, Qu WF, Ding ZB, Peng YF, Zhou J, Fan J, Shi YH. Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. Br J Cancer 2020;123:92-100. [PMID: 32376890 DOI: 10.1038/s41416-020-0864-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Front Immunol 2021;12:655697. [PMID: 33815418 DOI: 10.3389/fimmu.2021.655697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
67 Li X, Hu P, Liu J, Zhang J, Liu Q. Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. Future Oncol 2020;16:103-15. [PMID: 31933380 DOI: 10.2217/fon-2019-0761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
68 Norouzian M, Mehdipour F, Balouchi Anaraki S, Ashraf MJ, Khademi B, Ghaderi A. Atypical Memory and Regulatory B Cell Subsets in Tumor Draining Lymph Nodes of Head and Neck Squamous Cell Carcinoma Correlate with Good Prognostic Factors. Head Neck Pathol 2020;14:645-56. [PMID: 31691165 DOI: 10.1007/s12105-019-01095-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Harris RJ, Cheung A, Ng JCF, Laddach R, Chenoweth AM, Crescioli S, Fittall M, Dominguez-Rodriguez D, Roberts J, Levi D, Liu F, Alberts E, Quist J, Santaolalla A, Pinder SE, Gillett C, Hammar N, Irshad S, Van Hemelrijck M, Dunn-Walters DK, Fraternali F, Spicer JF, Lacy KE, Tsoka S, Grigoriadis A, Tutt ANJ, Karagiannis SN. Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. Cancer Res 2021;81:4290-304. [PMID: 34224371 DOI: 10.1158/0008-5472.CAN-20-3773] [Reference Citation Analysis]
70 Yeong J, Tan T, Chow ZL, Cheng Q, Lee B, Seet A, Lim JX, Lim JCT, Ong CCH, Thike AA, Saraf S, Tan BYC, Poh YC, Yee S, Liu J, Lim E, Iqbal J, Dent R, Tan PH. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. J Clin Pathol 2020;73:557-62. [PMID: 31969377 DOI: 10.1136/jclinpath-2019-206252] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
71 Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9:479-90. [PMID: 33083276 DOI: 10.1159/000509554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
72 Sachdeva M, Arora SK. Prognostic role of immune cells in hepatocellular carcinoma. EXCLI J 2020;19:718-33. [PMID: 32636725 DOI: 10.17179/excli2020-1455] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
73 Li T, Zhang X, Lv Z, Gao L, Yan H. Increased Expression of Myeloid-Derived Suppressor Cells in Patients with HBV-Related Hepatocellular Carcinoma. Biomed Res Int 2020;2020:6527192. [PMID: 32258134 DOI: 10.1155/2020/6527192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
74 Seow DYB, Yeong JPS, Lim JX, Chia N, Lim JCT, Ong CCH, Tan PH, Iqbal J. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. Breast Cancer Res Treat 2020;180:369-77. [PMID: 32034580 DOI: 10.1007/s10549-020-05548-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
75 Tay C, Kanellakis P, Hosseini H, Cao A, Toh BH, Bobik A, Kyaw T. B Cell and CD4 T Cell Interactions Promote Development of Atherosclerosis. Front Immunol 2019;10:3046. [PMID: 31998318 DOI: 10.3389/fimmu.2019.03046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
76 Huo J, Wu L, Zang Y. Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma. Med Sci Monit 2020;26:e925494. [PMID: 32945289 DOI: 10.12659/MSM.925494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
77 Mu D, Qin F, Li B, Zhou Q. Identification of the Sixth Complement Component as Potential Key Genes in Hepatocellular Carcinoma via Bioinformatics Analysis. Biomed Res Int 2020;2020:7042124. [PMID: 33083480 DOI: 10.1155/2020/7042124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Chakraborty D, Ivan C, Amero P, Khan M, Rodriguez-Aguayo C, Başağaoğlu H, Lopez-Berestein G. Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer. Cancers (Basel) 2021;13:3450. [PMID: 34298668 DOI: 10.3390/cancers13143450] [Reference Citation Analysis]
79 Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, Liu SJ, Jia LT, Wang L, Chen BL. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics 2020;10:10619-33. [PMID: 32929370 DOI: 10.7150/thno.44871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
80 Shen Q, Hu G, Wu J, Lv L. A new clinical prognostic nomogram for liver cancer based on immune score. PLoS One 2020;15:e0236622. [PMID: 32730361 DOI: 10.1371/journal.pone.0236622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, Lye WK, Putti TC, Dent R, Lim E, Thike AA, Tan PH, Iqbal J. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. Front Immunol 2018;9:1209. [PMID: 29899747 DOI: 10.3389/fimmu.2018.01209] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
82 Mishra AK, Kadoishi T, Wang X, Driver E, Chen Z, Wang XJ, Wang JH. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. Oncotarget 2016;7:81341-56. [PMID: 27835902 DOI: 10.18632/oncotarget.13228] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
83 Dwivedi S, Rendón-Huerta EP, Ortiz-Navarrete V, Montaño LF. CD38 and Regulation of the Immune Response Cells in Cancer. J Oncol 2021;2021:6630295. [PMID: 33727923 DOI: 10.1155/2021/6630295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Zhang Y, Mi K, Li Z, Qiang L, Lv M, Wu Y, Yuan L, Jin S. Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer. Front Oncol 2021;11:705869. [PMID: 34277450 DOI: 10.3389/fonc.2021.705869] [Reference Citation Analysis]
85 Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, Tao CY, Tang Z, Zhou PY, Fang Y, Qu WF, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Lau WY, Fan J, Shi YH. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Med 2019;17:106. [PMID: 31164128 DOI: 10.1186/s12916-019-1341-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
86 Ding W, Xu X, Qian Y, Xue W, Wang Y, Du J, Jin L, Tan Y. Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2018;97:e13301. [PMID: 30557978 DOI: 10.1097/md.0000000000013301] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 14.5] [Reference Citation Analysis]
87 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 62] [Article Influence: 96.0] [Reference Citation Analysis]
88 Qin M, Wang D, Fang Y, Zheng Z, Liu X, Wu F, Wang L, Li X, Hui B, Ma S, Tang W, Pan X. Current Perspectives on B Lymphocytes in the Immunobiology of Hepatocellular Carcinoma. Front Oncol 2021;11:647854. [PMID: 34235074 DOI: 10.3389/fonc.2021.647854] [Reference Citation Analysis]
89 Duffy AG, Makarova-Rusher OV, Greten TF. The case for immune-based approaches in biliary tract carcinoma. Hepatology 2016;64:1785-91. [PMID: 27177447 DOI: 10.1002/hep.28635] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
90 Kuroda H, Jamiyan T, Yamaguchi R, Kakumoto A, Abe A, Harada O, Masunaga A. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes. Clin Transl Oncol 2021. [PMID: 34089486 DOI: 10.1007/s12094-021-02652-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Wang J, Lun L, Jiang X, Wang Y, Li X, Du G, Wang J. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma. Int Immunopharmacol 2021;97:107675. [PMID: 33964809 DOI: 10.1016/j.intimp.2021.107675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Ma Z, Shiao SL, Yoshida EJ, Swartwood S, Huang F, Doche ME, Chung AP, Knudsen BS, Gertych A. Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate. Diagn Pathol 2017;12:69. [PMID: 28923066 DOI: 10.1186/s13000-017-0658-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
93 Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, Lim TKH, Yeong J, Toh HC, Lee SY, Chan CY, Goh BK, Chung A, Heikenwälder M, Ng IO, Chow P, Albani S, Chew V. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut 2019;68:916-27. [PMID: 29970455 DOI: 10.1136/gutjnl-2018-316510] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 24.7] [Reference Citation Analysis]
94 Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Baba H. Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer. Ann Surg 2020;271:693-700. [PMID: 30308614 DOI: 10.1097/SLA.0000000000002985] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 43.0] [Reference Citation Analysis]
95 Yeong J, Suteja L, Simoni Y, Lau KW, Tan AC, Li HH, Lim S, Loh JH, Wee FYT, Nerurkar SN, Takano A, Tan EH, Lim TKH, Newell EW, Tan DSW. Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC. J Thorac Oncol 2021;16:1349-58. [PMID: 33975004 DOI: 10.1016/j.jtho.2021.04.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Zhang C, Li J, Wang H, Song SW. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. Oncotarget 2016;7:73971-83. [PMID: 27738332 DOI: 10.18632/oncotarget.12605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
97 Ning G, Li Y, Chen W, Tang W, Shou D, Luo Q, Chen H, Zhou Y. Identification of New Biomarker for Prediction of Hepatocellular Carcinoma Development in Early-Stage Cirrhosis Patients. J Oncol 2021;2021:9949492. [PMID: 34335764 DOI: 10.1155/2021/9949492] [Reference Citation Analysis]
98 Shafique Y, Qureshi MA, Khan S, Mirza T. Differential Immune Landscape of Hepatocellular Carcinoma Suggests Potential role of Macrophages in Hepatocarcinogenesis. Pak J Med Sci 2021;37:858-62. [PMID: 34104178 DOI: 10.12669/pjms.37.3.2973] [Reference Citation Analysis]
99 Hladíková K, Koucký V, Bouček J, Laco J, Grega M, Hodek M, Zábrodský M, Vošmik M, Rozkošová K, Vošmiková H, Čelakovský P, Chrobok V, Ryška A, Špíšek R, Fialová A. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells. J Immunother Cancer 2019;7:261. [PMID: 31623665 DOI: 10.1186/s40425-019-0726-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
100 Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz B, Santoro A, Rimassa L. Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. Oncotarget 2017;8:14408-15. [PMID: 28122337 DOI: 10.18632/oncotarget.14797] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
101 Sautès-fridman C, Verneau J, Sun C, Moreira M, Chen TW, Meylan M, Petitprez F, Fridman WH. Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. Seminars in Immunology 2020;48:101406. [DOI: 10.1016/j.smim.2020.101406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
102 Yeong J, Lim JCT, Lee B, Li H, Ong CCH, Thike AA, Yeap WH, Yang Y, Lim AYH, Tay TKY, Liu J, Wong SC, Chen J, Lim EH, Iqbal J, Dent R, Newell EW, Tan PH. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. J Immunother Cancer 2019;7:34. [PMID: 30728081 DOI: 10.1186/s40425-019-0499-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 17.0] [Reference Citation Analysis]
103 Brunner SM, Itzel T, Rubner C, Kesselring R, Griesshammer E, Evert M, Teufel A, Schlitt HJ, Fichtner-Feigl S. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017;8:71002-71011. [PMID: 29050338 DOI: 10.18632/oncotarget.20238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
104 Wu J, Li X, Song W, Fang Y, Yu L, Liu S, Churilov LP, Zhang F. The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours. Autoimmun Rev. 2017;16:1270-1281. [PMID: 29042252 DOI: 10.1016/j.autrev.2017.10.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
105 Rizvi S, Wang J, El-Khoueiry AB. Liver Cancer Immunity. Hepatology 2021;73 Suppl 1:86-103. [PMID: 32516437 DOI: 10.1002/hep.31416] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
106 Chen S, Feng S, Wei J, Liu F, Li B, Li X, Hou Y, Gu D, Tang M, Xiao H, Jia Y, Peng S, Tian J, Kuang M. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging.Eur Radiol. 2019;29:4177-4187. [PMID: 30666445 DOI: 10.1007/s00330-018-5986-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 19.5] [Reference Citation Analysis]
107 Wang T, Chen B, Meng T, Liu Z, Wu W. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma. Bioengineered 2021;12:1555-75. [PMID: 33955820 DOI: 10.1080/21655979.2021.1918538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
108 Zhang FP, Huang YP, Luo WX, Deng WY, Liu CQ, Xu LB, Liu C. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. World J Gastroenterol 2020;26:134-53. [PMID: 31969776 DOI: 10.3748/wjg.v26.i2.134] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
109 Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, Loh E, Chang KTE, Tan TC, Zhai W, Chan JKY, Chow EK, Chee CE, Lee GH, Dan YY, Chow PK, Toh HC, Lim SG, Chen Q. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut 2018;67:1845-54. [PMID: 29602780 DOI: 10.1136/gutjnl-2017-315201] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 18.0] [Reference Citation Analysis]
110 Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222-232. [PMID: 29379119 DOI: 10.1038/s41590-018-0044-z] [Cited by in Crossref: 281] [Cited by in F6Publishing: 255] [Article Influence: 93.7] [Reference Citation Analysis]
111 Lai CPT, Yeong JPS, Tan AS, Ong CHC, Lee B, Lim JCT, Thike AA, Iqbal J, Dent RA, Lim EH, Tan PH. Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence. Breast Cancer Res Treat 2019;178:295-305. [PMID: 31410680 DOI: 10.1007/s10549-019-05396-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
112 Wee YTF, Alkaff SMF, Lim JCT, Loh JJH, Hilmy MH, Ong C, Nei WL, Jain A, Lim A, Takano A, Azhar R, Wan WK, Newell E, Yeong J, Lim TKH. An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours. Ann Diagn Pathol 2018;37:12-9. [PMID: 30218928 DOI: 10.1016/j.anndiagpath.2018.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
113 Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, Reiberger T, Jensen-Jarolim E, Eferl R, Trauner M. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep 2018;8:6220. [PMID: 29670256 DOI: 10.1038/s41598-018-24437-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 22.7] [Reference Citation Analysis]
114 Tan AS, Yeong JPS, Lai CPT, Ong CHC, Lee B, Lim JCT, Thike AA, Iqbal J, Dent RA, Lim EH, Tan PH. The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. Virchows Arch 2019;475:709-25. [PMID: 31407032 DOI: 10.1007/s00428-019-02635-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
115 Wang Z, Guo X, Gao L, Wang Y, Guo Y, Xing B, Ma W. Classification of pediatric gliomas based on immunological profiling: implications for immunotherapy strategies. Mol Ther Oncolytics 2021;20:34-47. [PMID: 33575469 DOI: 10.1016/j.omto.2020.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
116 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021;13:795-824. [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Reference Citation Analysis]
117 Hsiao YW, Chiu LT, Chen CH, Shih WL, Lu TP. Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. Genes (Basel) 2019;10:E630. [PMID: 31434354 DOI: 10.3390/genes10080630] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
118 Zhang H, Qiu C, Zeng H, Zhu W, Lyu W, Lao X. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma. Genet Test Mol Biomarkers 2021;25:504-14. [PMID: 34280005 DOI: 10.1089/gtmb.2020.0093] [Reference Citation Analysis]
119 Spear S, Candido JB, McDermott JR, Ghirelli C, Maniati E, Beers SA, Balkwill FR, Kocher HM, Capasso M. Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells. Front Immunol 2019;10:542. [PMID: 30972056 DOI: 10.3389/fimmu.2019.00542] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
120 Tang M, Zhou Q, Huang M, Sun K, Wu T, Li X, Liao B, Chen L, Liao J, Peng S, Chen S, Feng ST. Nomogram development and validation to predict hepatocellular carcinoma tumor behavior by preoperative gadoxetic acid-enhanced MRI. Eur Radiol 2021. [PMID: 33877387 DOI: 10.1007/s00330-021-07941-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Liu T, Wu H, Qi J, Qin C, Zhu Q. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma. Cancer Med 2020;9:7440-52. [PMID: 32815653 DOI: 10.1002/cam4.3406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
122 Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH. Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. Front Immunol 2019;10:2093. [PMID: 31552039 DOI: 10.3389/fimmu.2019.02093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
123 Navarro J, Kang I, Hwang HK, Yoon DS, Lee WJ, Kang CM. Glucose to Lymphocyte Ratio as a Prognostic Marker in Patients With Resected pT2 Gallbladder Cancer. J Surg Res 2019;240:17-29. [PMID: 30909062 DOI: 10.1016/j.jss.2019.02.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
124 Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol 2017;24:311-35. [PMID: 28777143 DOI: 10.1097/PAP.0000000000000161] [Cited by in Crossref: 220] [Cited by in F6Publishing: 135] [Article Influence: 73.3] [Reference Citation Analysis]
125 Wang L, Yang Z, Cao Y. Regulatory T cell and activated natural killer cell infiltration in hepatocellular carcinoma: immune cell profiling using the CIBERSORT. Ann Transl Med 2020;8:1483. [PMID: 33313228 DOI: 10.21037/atm-20-5830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
126 Wo YJ, Gan ASP, Lim X, Tay ISY, Lim S, Lim JCT, Yeong JPS. The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. Cells 2019;9:E26. [PMID: 31861847 DOI: 10.3390/cells9010026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
127 Lin Y, Wang S, Bremer E, Zhang H. Harnessing the soil: reshaping the tumor microenvironment towards an antitumor immune state by low-dose metformin. Cancer Commun (Lond) 2021;41:637-41. [PMID: 34288597 DOI: 10.1002/cac2.12196] [Reference Citation Analysis]
128 Wang J, Zhang L, Kang D, Yang D, Tang Y. Activation of PGE2/EP2 and PGE2/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8+ T cells in patients with lung cancer. Oncol Lett 2018;15:552-8. [PMID: 29285200 DOI: 10.3892/ol.2017.7279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
129 Tien TZ, Lee JNLW, Lim JCT, Chen XY, Thike AA, Tan PH, Yeong JPS. Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence. Histopathology 2021;79:139-59. [PMID: 33400265 DOI: 10.1111/his.14328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Kim M, Lee SJ, Shin S, Park KS, Park SY, Lee CH. Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells. Sci Rep 2018;8:10668. [PMID: 30006566 DOI: 10.1038/s41598-018-29048-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
131 Fridman WH, Petitprez F, Meylan M, Chen TW, Sun CM, Roumenina LT, Sautès-Fridman C. B cells and cancer: To B or not to B? J Exp Med 2021;218:e20200851. [PMID: 33601413 DOI: 10.1084/jem.20200851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
132 Saviano A, Roehlen N, Virzì A, Roca Suarez AA, Hoshida Y, Lupberger J, Baumert TF. Stromal and Immune Drivers of Hepatocarcinogenesis. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 317-31. [DOI: 10.1007/978-3-030-21540-8_15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021;21:541-57. [PMID: 34326518 DOI: 10.1038/s41568-021-00383-9] [Reference Citation Analysis]
134 Schlößer HA, Thelen M, Lechner A, Wennhold K, Garcia-Marquez MA, Rothschild SI, Staib E, Zander T, Beutner D, Gathof B, Gilles R, Cukuroglu E, Göke J, Shimabukuro-Vornhagen A, Drebber U, Quaas A, Bruns CJ, Hölscher AH, Von Bergwelt-Baildon MS. B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. Oncoimmunology 2019;8:e1512458. [PMID: 30546950 DOI: 10.1080/2162402X.2018.1512458] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
135 Guo FF, Cui JW. The Role of Tumor-Infiltrating B Cells in Tumor Immunity. J Oncol 2019;2019:2592419. [PMID: 31662750 DOI: 10.1155/2019/2592419] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
136 Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L, Yu Q, Dai W, Wu J, Zhou Y, Guo C. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 2021;40:250. [PMID: 34372912 DOI: 10.1186/s13046-021-02030-5] [Reference Citation Analysis]
137 N J, J T, Sl N, Gt B. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. Oncoimmunology 2021;10:1900508. [PMID: 33854820 DOI: 10.1080/2162402X.2021.1900508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, Chua C, Leong JY, Lim KH, Toh HC, Lee SY, Chan CY, Goh BKP, Chung A, Chow PKH, Albani S. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A 2017;114:E5900-9. [PMID: 28674001 DOI: 10.1073/pnas.1706559114] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 22.0] [Reference Citation Analysis]
139 Akkiz H, Carr BI, Bag HG, Karaoğullarından Ü, Yalçın K, Ekin N, Özakyol A, Altıntaş E, Balaban HY, Şimşek H, Uyanıkoğlu A, Balkan A, Kuran S, Üsküdar O, Ülger Y, Güney B, Delik A. Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma. Int J Clin Pract 2021;75:e13593. [PMID: 32583494 DOI: 10.1111/ijcp.13593] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
140 Kuroda H, Jamiyan T, Yamaguchi R, Kakumoto A, Abe A, Harada O, Masunaga A. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. BMC Cancer 2021;21:286. [PMID: 33726701 DOI: 10.1186/s12885-021-08009-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
141 Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma. Comput Struct Biotechnol J 2021;19:2775-89. [PMID: 34093992 DOI: 10.1016/j.csbj.2021.03.033] [Reference Citation Analysis]
142 Bedon L, Dal Bo M, Mossenta M, Busato D, Toffoli G, Polano M. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. Int J Mol Sci 2021;22:1075. [PMID: 33499054 DOI: 10.3390/ijms22031075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Curran CS, Sharon E. PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. Semin Oncol. 2017;44:428-432. [PMID: 29935904 DOI: 10.1053/j.seminoncol.2017.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
144 Xie K, Xu L, Wu H, Liao H, Luo L, Liao M, Gong J, Deng Y, Yuan K, Wu H, Zeng Y. OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis. Oncoimmunology 2018;7:e1404214. [PMID: 29632718 DOI: 10.1080/2162402X.2017.1404214] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
145 Lin T, Zhang E, Mai PP, Zhang YZ, Chen X, Peng LS. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20204312. [PMID: 34085699 DOI: 10.1042/BSR20204312] [Reference Citation Analysis]
146 Schwabe RF, Greten TF. Gut microbiome in HCC - Mechanisms, diagnosis and therapy. J Hepatol. 2020;72:230-238. [PMID: 31954488 DOI: 10.1016/j.jhep.2019.08.016] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 51.0] [Reference Citation Analysis]
147 Edin S, Kaprio T, Hagström J, Larsson P, Mustonen H, Böckelman C, Strigård K, Gunnarsson U, Haglund C, Palmqvist R. The Prognostic Importance of CD20+ B lymphocytes in Colorectal Cancer and the Relation to Other Immune Cell subsets. Sci Rep 2019;9:19997. [PMID: 31882709 DOI: 10.1038/s41598-019-56441-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
148 Shao Y, Chen B, Ou D, Lin Z, Hsu C, Wang M, Cheng A, Hsu C. Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. Aliment Pharmacol Ther 2017;46:722-30. [DOI: 10.1111/apt.14270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
149 Meng Q, Valentini D, Rao M, Dodoo E, Maeurer M. CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors. Sci Rep 2018;8:17079. [PMID: 30459443 DOI: 10.1038/s41598-018-34710-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
150 Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020;8. [PMID: 32847986 DOI: 10.1136/jitc-2020-000987] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
151 Lam JH, Hong M, Koo SL, Chua CWL, Lim KL, Wee F, Wan WK, Leow WQ, Yeo JG, Tan IBH, Yeong J, Lim TKH, Lim TS. CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer. Cancer Immunol Immunother 2021;70:2353-65. [PMID: 33527196 DOI: 10.1007/s00262-021-02859-x] [Reference Citation Analysis]
152 Hou J, Zhang H, Sun B, Karin M. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. J Hepatol 2020;72:167-82. [PMID: 31449859 DOI: 10.1016/j.jhep.2019.08.014] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 23.5] [Reference Citation Analysis]
153 Yasumaru CC, Xavier JG, Strefezzi RF, Salles-Gomes COM. Intratumoral T-Lymphocyte Subsets in Canine Oral Melanoma and Their Association With Clinical and Histopathological Parameters. Vet Pathol 2021;58:491-502. [PMID: 33764216 DOI: 10.1177/0300985821999321] [Reference Citation Analysis]
154 Jiang Y, Chen S, Li Q, Liang J, Lin W, Li J, Liu Z, Wen M, Cao M, Hong J. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration. Front Immunol 2021;12:612139. [PMID: 33679751 DOI: 10.3389/fimmu.2021.612139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Dhenni R, Phan TG. The geography of memory B cell reactivation in vaccine-induced immunity and in autoimmune disease relapses. Immunol Rev 2020;296:62-86. [PMID: 32472583 DOI: 10.1111/imr.12862] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
156 Tian M, Liu W, Tao C, Tang Z, Zhou Y, Song S, Jin L, Wang H, Jiang X, Zhou P, Fang Y, Qu W, Ding Z, Peng Y, Fu X, Qiu S, Zhou J, Fan J, Shi Y. Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: ISICC -applied prediction model. Cancer Sci 2020;111:1084-92. [PMID: 31971309 DOI: 10.1111/cas.14315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
157 Hamza A, Khan U, Khurram MS, Abraham R, Mazzara P, Hadid T, Kafri Z. Prognostic Utility of Tumor-Infiltrating Lymphocytes in Noncolorectal Gastrointestinal Malignancies. Int J Surg Pathol 2019;27:263-7. [PMID: 30426804 DOI: 10.1177/1066896918809460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
158 Wang J, Zhang C, Li A, Cao F, Liu D, Li F, Luo T. A Prognostic Nomogram Based on Immune Scores Predicts Postoperative Survival for Patients with Hepatocellular Carcinoma. Biomed Res Int 2020;2020:1542394. [PMID: 32724794 DOI: 10.1155/2020/1542394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Liu M, Sun Q, Wei F, Ren X. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer Biol Med 2020;17:626-39. [PMID: 32944395 DOI: 10.20892/j.issn.2095-3941.2020.0112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]